Clinical Trial Update: Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a phosphodiesterase-5 inhibitor for Eisenmenger syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eisenmenger Syndrome

Drugs mentioned

• Phosphodiesterase-5 inhibitor

Snippet

Sponsor: Govind Ballabh Pant Hospital | Conditions: Eisenmenger Syndrome | Phase 2 | Status: COMPLETED